Compare Vanguard High Dividend Yield ETF (VYM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard High Dividend Yield ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard High Dividend Yield ETF trades at $166.54, while State Street SPDR S&P Biotech ETF trades at $159.9. Which is the better fit depends on your goals.
| VYM | XBI | |
|---|---|---|
52-Week High | $166.14 | $164.28 |
52-Week Low | $136.63 | $86.92 |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VYM trades at $166.36, up 0.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF focuses on high dividend yield stocks, offering income appeal, though key valuation ratios like P/E and P/B are not available. Recent news highlights institutional position adjustments and discussions on its role in retirement income portfolios.
Outlook is mixed: technical indicators suggest near-term caution due to overbought conditions, while the dividend strategy supports long-term income. Risks include market volatility and yield compression. Analyst sentiment is generally positive for income-focused investors, but monitor for pullbacks.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
